\-\ Texto\\:\\ \ \(0\)\
\-\ n\\/a\ \(127\)\
\-\ patient\\ was\\ referred\\ to\\ gynecology\\ by\\ primary\\ care\\ clinician\\.\ \(0\)\
\-\ sonographic\\ images\\ demonstrates\\ a\\ focal\\ hypoechoic\\ area\\ in\\ the\\ junctional\\ zone\\ posteriorly\\ and\\ at\\ the\\ level\\ of\\ the\\ fundus\\.\\ \\ also\\ present\\ were\\ well\\ circumscribed\\ intramural\\ hypoechoic\\ areas\\ compatible\\ with\\ fibroids\\ \\(not\\ shown\\)\\.\ \(0\)\
\-\ mr\\:\ \(0\)\
\-\ axial\\ and\\ sagittal\\ t2\\ weighted\\ sequences\\ of\\ the\\ pelvis\\ demonstrate\\ a\\ focal\\ area\\ of\\ thickening\\ of\\ the\\ junctional\\ zone\\ posteriorly\\ compatible\\ with\\ focal\\ adenomyosis\\.\ \(0\)\
\-\ adenomyosis\ \(10\)\
\-\ adenomyosis\ \(10\)\
\-\ leiomyoma\ \(85\)\
\-\ 35\\ year\\ old\\ with\\ heavy\\ menses\\ and\\ clotting\\.\ \(1\)\
\-\ adenomyosis\\ consists\\ of\\ endometrial\\ glands\\ and\\ stroma\\ within\\ the\\ myometrium\\ with\\ associated\\ myometrial\\ hypertrophy\\.\\ \\ clinically\\,\\ patients\\ present\\ with\\ excessive\\ uterine\\ bleeding\\ with\\ worsening\\ dysmenorrhea\\.\\ \\ these\\ symptoms\\ are\\ nonspecific\\ and\\ are\\ also\\ a\\ sequelae\\ of\\ leiomyoma\\,\\ endometriosis\\ and\\ endometrial\\ polyps\\.\\ \\ adenomyosis\\ occurs\\ in\\ premenopausal\\ women\\.\\ \\ adenomyosis\\ may\\ be\\ diffuse\\ or\\ focal\\.\\ \ \(0\)\
\-\ sonographic\\ findings\\ include\\ uterine\\ enlargement\\ not\\ explained\\ by\\ the\\ presence\\ of\\ leiomyomas\\,\\ asymmetric\\ thickening\\ of\\ the\\ myometrial\\ wall\\,\\ poorly\\ circumscribed\\ areas\\ in\\ the\\ myometrium\\,\\ cysts\\ of\\ varying\\ sizes\\ and\\ increased\\ echogenicity\\ of\\ the\\ myometrium\\.\\ \\ however\\,\\ features\\ are\\ subjective\\.\ \(0\)\
\-\ adenomyosis\\ on\\ t1\\ weighted\\ sequences\\ may\\ not\\ be\\ apparent\\.\\ \\ t2\\ weighted\\ images\\ exhibit\\ low\\ signal\\ intensity\\ in\\ the\\ junctional\\ zone\\ which\\ exceeds\\ a\\ short\\ axis\\ measurement\\ of\\ 11mm\\ in\\ adenomyosis\\.\\ \\ small\\ foci\\ of\\ increased\\ t1\\ and\\ t2\\ signal\\ may\\ represent\\ associated\\ hemorrhage\\ in\\ these\\ lesions\\.\ \(0\)\
\-\ this\\ patient\\ demonstrated\\ a\\ focal\\ area\\ of\\ decreased\\ echogenicity\\ confirmed\\ on\\ mr\\ cmpatible\\ with\\ focal\\ adenomyosis\\.\ \(0\)\
\-\ references\\:\ \(0\)\
\-\ olson\\,\\ m\\,\\ posniak\\,\\ h\\,\\ tempany\\,\\ c\\,\\ and\\ dudiak\\,\\ c\\.\\ \\ \\"mr\\ imaging\\ of\\ the\\ female\\ pelvic\\ region\\.\\"\\ \\ radiographics\\ 1992\\;\\ 12\\:\\ 445\\-465\\.\ \(0\)\
\-\ reinhold\\,\\ c\\,\\ tafazoli\\,\\ f\\,\\ mehio\\,\\ a\\,\\ wang\\,\\ l\\,\\ atri\\,\\ m\\,\\ siegelman\\,\\ e\\,\\ and\\ rohoman\\,\\ l\\.\\ \\ \\"uterine\\ adenomyosis\\:\\ endovaginal\\ us\\ and\\ mr\\ imaging\\ features\\ with\\ histopatholigic\\ correlation\\"\\.\\ \\ radiographics\\ 1999\\;\\ 19\\:\\ s147\\-s160\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ adenomyosis\\:\\ 0\\.6038822283098468\ \(0\)\
\-\ myometrium\\:\\ 0\\.19035255068348134\ \(0\)\
\-\ junctional\\:\\ 0\\.1877200383870095\ \(0\)\
\-\ focal\\:\\ 0\\.17050743803267068\ \(0\)\
\-\ myometrial\\:\\ 0\\.14040950428799373\ \(0\)\
\-\ zone\\:\\ 0\\.13771154441942807\ \(0\)\
\-\ uterine\\:\\ 0\\.13309989125883254\ \(0\)\
\-\ of\\:\\ 0\\.13016299233197853\ \(0\)\
\-\ mr\\:\\ 0\\.12296268946103543\ \(0\)\
\-\ the\\:\\ 0\\.11375788372418846\ \(0\)\
\-\ and\\:\\ 0\\.10798933075859787\ \(0\)\
\-\ weighted\\:\\ 0\\.1063140283092971\ \(0\)\
\-\ leiomyoma\\:\\ 0\\.0986745286058433\ \(0\)\
\-\ endometrial\\:\\ 0\\.09705605536673967\ \(0\)\
\-\ radiographics\\:\\ 0\\.09586575113558553\ \(0\)\
\-\ compatible\\:\\ 0\\.09502571574873327\ \(0\)\
\-\ echogenicity\\:\\ 0\\.09273333283055869\ \(0\)\
\-\ area\\:\\ 0\\.09233160392724289\ \(0\)\
\-\ sonographic\\:\\ 0\\.08551018378036725\ \(0\)\
\-\ posteriorly\\:\\ 0\\.08375517558271933\ \(0\)\
\-\ t2\\:\\ 0\\.08200020759569983\ \(0\)\
\-\ hypoechoic\\:\\ 0\\.08118746124418627\ \(0\)\
\-\ features\\:\\ 0\\.07645508795841711\ \(0\)\
\-\ sequences\\:\\ 0\\.07601322725736138\ \(0\)\
\-\ cmpatible\\:\\ 0\\.07597768793718307\ \(0\)\
\-\ olson\\:\\ 0\\.07597768793718307\ \(0\)\
\-\ posniak\\:\\ 0\\.07597768793718307\ \(0\)\
\-\ tempany\\:\\ 0\\.07597768793718307\ \(0\)\
\-\ dudiak\\:\\ 0\\.07597768793718307\ \(0\)\
\-\ reinhold\\:\\ 0\\.07597768793718307\ \(0\)\
\-\ tafazoli\\:\\ 0\\.07597768793718307\ \(0\)\
\-\ mehio\\:\\ 0\\.07597768793718307\ \(0\)\
\-\ atri\\:\\ 0\\.07597768793718307\ \(0\)\
\-\ rohoman\\:\\ 0\\.07597768793718307\ \(0\)\
\-\ histopatholigic\\:\\ 0\\.07597768793718307\ \(0\)\
\-\ with\\:\\ 0\\.07442329410793186\ \(0\)\
\-\ circumscribed\\:\\ 0\\.07358312458282404\ \(0\)\
\-\ premenopausal\\:\\ 0\\.0726007369790982\ \(0\)\
\-\ siegelman\\:\\ 0\\.0726007369790982\ \(0\)\
\-\ may\\:\\ 0\\.07172450934466625\ \(0\)\
\-\ in\\:\\ 0\\.07091260794332946\ \(0\)\
\-\ 11mm\\:\\ 0\\.06834628192218938\ \(0\)\
\-\ dysmenorrhea\\:\\ 0\\.066827801185912\ \(0\)\
\-\ thickening\\:\\ 0\\.06464269593929203\ \(0\)\
\-\ areas\\:\\ 0\\.06451101800707766\ \(0\)\
\-\ leiomyomas\\:\\ 0\\.06345085022782712\ \(0\)\
\-\ exceeds\\:\\ 0\\.06345085022782712\ \(0\)\
\-\ wang\\:\\ 0\\.06345085022782712\ \(0\)\
\-\ gynecology\\:\\ 0\\.06177954711505793\ \(0\)\
\-\ endovaginal\\:\\ 0\\.06177954711505793\ \(0\)\
\-\ clotting\\:\\ 0\\.05977100822345926\ \(0\)\
\-\ t1\\:\\ 0\\.05920250549960431\ \(0\)\
\-\ 1992\\:\\ 0\\.05680041033581695\ \(0\)\
\-\ endometriosis\\:\\ 0\\.05639405726537439\ \(0\)\
\-\ not\\:\\ 0\\.05626660560231039\ \(0\)\
\-\ stroma\\:\\ 0\\.05600661132187173\ \(0\)\
\-\ explained\\:\\ 0\\.05600661132187173\ \(0\)\
\-\ menses\\:\\ 0\\.05563639100155234\ \(0\)\
\-\ subjective\\:\\ 0\\.054941940114009456\ \(0\)\
\-\ exhibit\\:\\ 0\\.054941940114009456\ \(0\)\
\-\ sizes\\:\\ 0\\.054615287037798485\ \(0\)\
\-\ measurement\\:\\ 0\\.054615287037798485\ \(0\)\
\-\ are\\:\\ 0\\.05408283772002662\ \(0\)\
\-\ heavy\\:\\ 0\\.053998072430273054\ \(0\)\
\-\ signal\\:\\ 0\\.05386332471749033\ \(0\)\
\-\ clinician\\:\\ 0\\.053705811360978975\ \(0\)\
\-\ fibroids\\:\\ 0\\.053705811360978975\ \(0\)\
\-\ these\\:\\ 0\\.05365697033014418\ \(0\)\
\-\ intramural\\:\\ 0\\.052885944764438246\ \(0\)\
\-\ increased\\:\\ 0\\.05138152337712679\ \(0\)\
\-\ excessive\\:\\ 0\\.051238336079713606\ \(0\)\
\-\ polyps\\:\\ 0\\.051238336079713606\ \(0\)\
\-\ glands\\:\\ 0\\.05042514570464477\ \(0\)\
\-\ sequelae\\:\\ 0\\.05042514570464477\ \(0\)\
\-\ associated\\:\\ 0\\.05008191076138714\ \(0\)\
\-\ imaging\\:\\ 0\\.0499354731441453\ \(0\)\
\-\ varying\\:\\ 0\\.04986345520836614\ \(0\)\
\-\ fundus\\:\\ 0\\.04933726430292165\ \(0\)\
\-\ present\\:\\ 0\\.04875711336888116\ \(0\)\
\-\ 1999\\:\\ 0\\.04779050311217026\ \(0\)\
\-\ correlation\\:\\ 0\\.04737743073047964\ \(0\)\
\-\ consists\\:\\ 0\\.0472441705141033\ \(0\)\
\-\ axis\\:\\ 0\\.045903848139809356\ \(0\)\
\-\ hypertrophy\\:\\ 0\\.0447496213826167\ \(0\)\
\-\ also\\:\\ 0\\.04469401123270262\ \(0\)\
\-\ nonspecific\\:\\ 0\\.04465220991145856\ \(0\)\
\-\ images\\:\\ 0\\.04395241372352288\ \(0\)\
\-\ poorly\\:\\ 0\\.042910770924511774\ \(0\)\
\-\ women\\:\\ 0\\.04275509189018362\ \(0\)\
\-\ asymmetric\\:\\ 0\\.04275509189018362\ \(0\)\
\-\ short\\:\\ 0\\.040835155811237984\ \(0\)\
\-\ by\\:\\ 0\\.040350394812889906\ \(0\)\
\-\ apparent\\:\\ 0\\.03974602471548593\ \(0\)\
\-\ represent\\:\\ 0\\.039533819966426895\ \(0\)\
\-\ clinically\\:\\ 0\\.039481602956258334\ \(0\)\
\-\ bleeding\\:\\ 0\\.038830992326012705\ \(0\)\
\-\ foci\\:\\ 0\\.038830992326012705\ \(0\)\
\-\ be\\:\\ 0\\.03854523441216813\ \(0\)\
\-\ 35\\:\\ 0\\.03809428376283222\ \(0\)\
\-\ references\\:\\ 0\\.0378768148586117\ \(0\)\
\-\ us\\:\\ 0\\.03779139271654924\ \(0\)\
\-\ 19\\:\\ 0\\.03762313273445083\ \(0\)\
\-\ occurs\\:\\ 0\\.03745820485315311\ \(0\)\
\-\ pelvic\\:\\ 0\\.03713783513132557\ \(0\)\
\-\ shown\\:\\ 0\\.036829333720505605\ \(0\)\
\-\ sagittal\\:\\ 0\\.03653185260350683\ \(0\)\
\-\ enlargement\\:\\ 0\\.03642298065006303\ \(0\)\
\-\ worsening\\:\\ 0\\.03627999712390646\ \(0\)\
\-\ cysts\\:\\ 0\\.03600118997401388\ \(0\)\
\-\ referred\\:\\ 0\\.03515458975421085\ \(0\)\
\-\ confirmed\\:\\ 0\\.035031656365989795\ \(0\)\
\-\ presence\\:\\ 0\\.0341358677684055\ \(0\)\
\-\ care\\:\\ 0\\.03394626575631222\ \(0\)\
\-\ intensity\\:\\ 0\\.03373473474566763\ \(0\)\
\-\ pelvis\\:\\ 0\\.033228281731035994\ \(0\)\
\-\ 12\\:\\ 0\\.03247702700397417\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.03180865777365838\ \(0\)\
\-\ patient\\:\\ 0\\.030904770138459402\ \(0\)\
\-\ diffuse\\:\\ 0\\.02979420159169342\ \(0\)\
\-\ decreased\\:\\ 0\\.029428225857811036\ \(0\)\
\-\ primary\\:\\ 0\\.029213084371824464\ \(0\)\
\-\ demonstrated\\:\\ 0\\.029197927705511897\ \(0\)\
\-\ wall\\:\\ 0\\.028900446588513123\ \(0\)\
\-\ level\\:\\ 0\\.028698356601309188\ \(0\)\
\-\ on\\:\\ 0\\.028697238511127966\ \(0\)\
\-\ region\\:\\ 0\\.028417906338778446\ \(0\)\
\-\ include\\:\\ 0\\.028267591439602037\ \(0\)\
\-\ however\\:\\ 0\\.028119941409537517\ \(0\)\
\-\ axial\\:\\ 0\\.027443070938074087\ \(0\)\
\-\ lesions\\:\\ 0\\.02728512073964029\ \(0\)\
\-\ low\\:\\ 0\\.027261084400185893\ \(0\)\
\-\ patients\\:\\ 0\\.02672657053844324\ \(0\)\
\-\ symptoms\\:\\ 0\\.025994388963429416\ \(0\)\
\-\ demonstrate\\:\\ 0\\.024698759939425424\ \(0\)\
\-\ small\\:\\ 0\\.024506888743371234\ \(0\)\
\-\ were\\:\\ 0\\.024489663120187962\ \(0\)\
\-\ demonstrates\\:\\ 0\\.023868147667826342\ \(0\)\
\-\ findings\\:\\ 0\\.023447737267855946\ \(0\)\
\-\ well\\:\\ 0\\.023004229520226255\ \(0\)\
\-\ female\\:\\ 0\\.02292542080812298\ \(0\)\
\-\ within\\:\\ 0\\.02188131119966645\ \(0\)\
\-\ which\\:\\ 0\\.021602944135621846\ \(0\)\
\-\ at\\:\\ 0\\.01794485802325568\ \(0\)\
\-\ was\\:\\ 0\\.016557455842311285\ \(0\)\
\-\ or\\:\\ 0\\.016527633939526908\ \(0\)\
\-\ this\\:\\ 0\\.016325045558821357\ \(0\)\
\-\ year\\:\\ 0\\.014641425954765351\ \(0\)\
\-\ old\\:\\ 0\\.01406083717194572\ \(0\)\
\-\ to\\:\\ 0\\.011877227680600242\ \(0\)\
